AcroMeta Group Limited (SGX: 43F) has announced a strategic move into the emerging field of ambient temperature cellular logistics (ATCLS) by signing a non-binding term sheet with Macro HRD SG Pte. Ltd. (Macro), a Singapore-based healthcare consultancy. The partnership will see AcroMeta acquire a strategic stake in Macro-ATCLS Pte. Ltd., the entity commercializing Macro’s ATCLS technology, and includes an option to secure an exclusive license to deploy the technology across Southeast Asia.
The ATCLS technology aims to transform the transportation of living cells and temperature-sensitive biological materials by eliminating reliance on conventional cold chains. It uses proprietary ambient-temperature preservation and reactivation methods, supported by a Gradient Equilibrium Decision Modeling (GEDM) platform for real-time governance and control. This allows dormant cells to be shipped at ambient temperatures and reactivated at the point of use, potentially reducing costs, fragility, and geographic limitations of current logistics.
The move targets rapidly expanding markets, including stem cells, CAR-T/immune-cell therapy, gene therapy, regenerative medicine, and organ transplantation. According to Macro’s management, the global cell-and-gene-therapy 3PL market was estimated at US$1.81 billion in 2025 and is projected to reach US$16.95 billion by 2035, a 25.1% CAGR. The serviceable addressable market for ATCLS is estimated at US$14.5 billion by 2032.
Lawrence Toh, Executive Director of AcroMeta, stated, “This proposed strategic partnership gives us the opportunity to build a position in an industry where cell and gene therapy logistics are expected to grow at double-digit rates in the years ahead. We see this as a natural extension of our strategy to grow our portfolio beyond our core operations.”
The exclusive licensing arrangement for Southeast Asia would grant AcroMeta rights to develop and commercialize the technology in agreed territories, including the right to appoint sub-licensees, and a first right to acquire additional territories. This could significantly expand the Group’s commercial reach.
AcroMeta, currently in facility management services, plans to continue evaluating strategic opportunities for long-term growth and value creation for shareholders. The company emphasizes disciplined capital allocation as it enters this next phase.
The information regarding market projections was provided by Macro’s management and has not been independently verified by AcroMeta’s board. The board has not audited the data.
This partnership positions AcroMeta to capitalize on the growing demand for cell and gene therapies, which require specialized logistics. By adopting ATCLS, the company could offer a disruptive solution that addresses the high costs and complexity of traditional cold-chain logistics, potentially making advanced therapies more accessible and affordable in Southeast Asia.
For more information on AcroMeta, visit www.AcroMeta.com. The original press release is available at www.newmediawire.com.
